Download PDF
Semin Liver Dis 2002; 22(3): 303-314
DOI: 10.1055/s-2002-34507
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Cyclooxygenase-2 and ERBB-2 in Cholangiocarcinoma: Potential Therapeutic Targets

Alphonse E. Sirica, Guan-Hua Lai, Kanenori Endo, Zichen Zhang, Byung-IL Yoon
  • Department of Pathology, Medical College of Virginia Campus of Virginia, Commonwealth University, Richmond, Virginia
Further Information

Publication History

Publication Date:
02 October 2002 (online)

    Permissions and Reprints

ABSTRACT

Cholangiocarcinoma is a rare but highly malignant primary hepatobiliary cancer with a high rate of mortality. Early diagnosis is difficult and current therapies are ineffective for the advanced disease. Although the molecular pathogenesis of cholangiocarcinoma is still poorly understood, there is increasing evidence to suggest that overexpression of the proto-oncogene-encoded receptor tyrosine kinase ERBB-2 together with upregulation of cyclooxygenase-2 (COX-2) may be an important feature of cholangiocarcinogenesis in both the human and the experimental rodent models. Evidence presented supports a strong positive correlation between ERBB-2 overexpression and cyclooxygenase upregulation in human cholangiocarcinogenesis. Combination drug targeting of ERBB-2 and of COX-2 was also found to act synergistically to suppress anchorage-independent growth and activate caspase-3 in cultured rat cholangiocarcinoma cells overexpressing both proteins. These findings suggest that aberrant expression of ERBB-2 and COX-2 is a common feature of human and rat cholangiocarcinomas and that targeting of both proteins may prove useful as a therapeutic strategy for this lethal cancer.

KEYWORDS

Cholangiocarcinogenesis - ERBB-2 - cyclooxygenase-2 - therapeutic targeting

REFERENCES

  • 1 Weber S M, Jarnagin W R, Klimstra D. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.  J Am Coll Surg . 2001;  193 384-391
    CrossrefPubMedGoogle Scholar
  • 2 Uenishi T, Hirohashi K, Kubo S. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma.  World J Surg . 2001;  25 865-869
    CrossrefPubMedGoogle Scholar
  • 3 Jarnagin W R, Fong Y, DeMatteo R P. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.  Ann Surg . 2001;  234 507-519
    CrossrefPubMedGoogle Scholar
  • 4 De Groen C P, Gores G J, LaRusso N F, Gunderson L L, Nagorney D M. Biliary tract cancers.  N Engl J Med . 1999;  341 1368-1378
    CrossrefPubMedGoogle Scholar
  • 5 Sirica A E, Gainey T W, Harrell M B, Caran N. Cholangiocarcinogenesis and biliary adaptation responses in hepatic injury. In: Sirica AE, Longnecker DS, eds. Biliary and Pancreatic Ductal Epithelia-Pathobiology and Pathophysiology New York: Marcel Dekker 1997: 229-290
    Google Scholar
  • 6 Chapman R W. Risk factors for biliary tract carcinogenesis.  Ann Oncol . 1999;  10(Suppl 4) S308-S311
    CrossrefPubMedGoogle Scholar
  • 7 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.  Hepatology . 2001;  33 1353-1357
    CrossrefPubMedGoogle Scholar
  • 8 Suzuki H, Isaji S, Pairojkul C, Uttaravichien T. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.  J Hepatobiliary Pancreat Surg . 2000;  7 206-211
    CrossrefPubMedGoogle Scholar
  • 9 Chu K-M, Lo C-M, Liu C-L, Fan S-T. Malignancy associated with hepatolithiasis.  Hepatogastroenterology . 1997;  44 352-357
    PubMedGoogle Scholar
  • 10 Su W-C, Shiesh S-C, Liu H-S, Chen C-Y, Chow N-H, Lin X-Z. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders.  Dig Dis Sci . 2001;  46 1387-1392
    CrossrefPubMedGoogle Scholar
  • 11 Chen T-C, Nakanuma Y, Zen Y, Chen M-F. Intraductal papillary neoplasia of the liver associated with hepatolithiasis.  Hepatology . 2001;  34 651-658
    CrossrefPubMedGoogle Scholar
  • 12 Ponsioen C IJ, Tytgat G NJ. Primary sclerosing cholangitis: a clinical review.  Am J Gastroenterol . 1998;  93 515-523
    CrossrefPubMedGoogle Scholar
  • 13 Harrison P M. Prevention of bile duct cancer in primary sclerosing cholangitis.  Ann Oncol . 1999;  10(Suppl 4) S208-S211
    CrossrefPubMedGoogle Scholar
  • 14 Komi N, Tamura T, Miyoshi Y. Histochemical and immunohistochemical studies on development of biliary carcinoma in forty-seven patients with choledochal cysts-special reference to intestinal metaplasia in the biliary duct.  Jpn J Surg . 1985;  15 273-278
    PubMedGoogle Scholar
  • 15 Imazu M, Iwai N, Tokiwa K, Shimotake T, Kimura O, Ono S. Factors of biliary carcinogenesis in choledochal cysts.  Eur J Pediatr Surg . 2001;  11 24-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Taylor-Robinson S D, Toledano M B, Arora S. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.  Gut . 2001;  48 816-820
    CrossrefPubMedGoogle Scholar
  • 17 Shirabe K, Shimada M, Harimoto N. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities.  Surgery . 2002;  131 S159-S164
    CrossrefPubMedGoogle Scholar
  • 18 Bathe O F, Pacheco J T, Ossi P B. Management of hilar bile duct carcinoma.  Hepatogastroenterlogy . 2001;  48 1289-1294
    PubMedGoogle Scholar
  • 19 Sirica A E, Lai G-H, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.  J Gastroenterol Hepatol . 2001;  16 363-372
    CrossrefPubMedGoogle Scholar
  • 20 Sirica A E, Endo K, Lai G-H, Demetris A J, Pairojkul C, Terada T. COX-2 and ERBB-2/NEU in human and rat cholangiocarcinomas: potential therapeutic targets.  Hepatology . 2001;  34 191A
    PubMedGoogle Scholar
  • 21 Lohrisch C, Piccart M. An overview of HER2.  Semin Oncol . 2001;  28(Suppl 18) 3-11
    PubMedGoogle Scholar
  • 22 Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.  Crit Rev Clin Lab Sci . 2000;  37 431-502
    PubMedGoogle Scholar
  • 23 Andrechek E R, Muller W J. Tyrosine kinase signaling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.  Breast Cancer Res . 2000;  2 211-216
    CrossrefPubMedGoogle Scholar
  • 24 Liu C H, Chang S-H, Narko K. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.  J Biol Chem . 2001;  276 18563-18569
    CrossrefPubMedGoogle Scholar
  • 25 Voravud N, Foster C S, Gilbertson J A, Sikora K, Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development.  Hum Pathol . 1989;  20 1163-1168
    PubMedGoogle Scholar
  • 26 Terada T, Ashida K, Endo K. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.  Histopathology . 1998;  33 325-331
    CrossrefPubMedGoogle Scholar
  • 27 Brunt E M, Swanson P E. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver.  Am J Clin Pathol . 1992;  97(Suppl 1) S53-S61
    PubMedGoogle Scholar
  • 28 Aishima S-I, Taguchi K-I, Sugimachi K. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.  Histopathology . 2002;  40 269-278
    CrossrefPubMedGoogle Scholar
  • 29 Ito Y, Takeda T, Sasaki Y. Expression and clinical significance of the erbB family in intrahepatic cholangiocarcinoma.  Pathol Res Pract . 2001;  197 95-100
    PubMedGoogle Scholar
  • 30 Chow N-H, Huang S-M, Chan S-H. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.  Anticancer Res . 1995;  15 1055-1060
    PubMedGoogle Scholar
  • 31 Collier J D, Guo K, Mathew J. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma.  J Hepatol . 1992;  14 377-380
    CrossrefPubMedGoogle Scholar
  • 32 Press M F, Hung G, Godolphin W, Slamon D J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.  Cancer Res . 1994;  54 2771-2777
    PubMedGoogle Scholar
  • 33 Chariyalertsak S, Sirikulchayanonta V, Mayer D. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.  Gut . 2001;  48 80-86
    CrossrefPubMedGoogle Scholar
  • 34 Hayashi N, Yamamoto H, Hiraoka N. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.  Hepatology . 2001;  34 638-650
    CrossrefPubMedGoogle Scholar
  • 35 Endo K, Yoon B I, Pairojkul C, Demetris A J, Sirica A E. ERBB-2 over-expression and cyclooxygenase-2 up-regulation in human cholangiocarcioma and associated risk conditions (in press).  Hepatology. 2002; 
    PubMedGoogle Scholar
  • 36 Koga H, Sakisaka S, Ohishi M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation.  Hepatology . 1999;  29 688-696
    CrossrefPubMedGoogle Scholar
  • 37 Ghosh M, Kawamoto T, Koike N. Cyclooxygenase expression in the gallbladder.  Int J Mol Med . 2000;  6 527-532
    PubMedGoogle Scholar
  • 38 Maronpot R R, Giles H D, Dykes D J, Irwin R D. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats.  Toxicol Pathol . 1991;  19 561-570
    PubMedGoogle Scholar
  • 39 Elmore L W, Sirica A E. ``Intestinal-type'' of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan.  Cancer Res . 1993;  53 254-259
    PubMedGoogle Scholar
  • 40 Sirica A E. Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis.  Toxicol Pathol . 1996;  24 90-99
    PubMedGoogle Scholar
  • 41 Sirica A E, Radaeva S, Caran N. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.  Am J Pathol . 1997;  151 1685-1694
    PubMedGoogle Scholar
  • 42 Radaeva S, Ferreira-Gonzalez A, Sirica A E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.  Hepatology . 1999;  29 1453-1462
    CrossrefPubMedGoogle Scholar
  • 43 Lai G-H, Sirica A E. Establishment of a novel rat cholangiocarcinoma cell culture model.  Carcinogenesis . 1999;  20 2335-2339
    CrossrefPubMedGoogle Scholar
  • 44 Shiraishi K, Kusano N, Okita S. Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers.  Oncology . 1999;  57 42-49
    PubMedGoogle Scholar
  • 45 Kiguchi K, Carbajal S, Chan K. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.  Cancer Res . 2001;  61 6971-6976
    Google Scholar
  • 46 Half E, Tang X M, Gwyn K. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.  Cancer Res . 2002;  62 1676-1681
    PubMedGoogle Scholar
  • 47 Vadlamudi R, Mandal M, Adam L. Regulation of cyclooxygenase-2 pathway by HER2 receptor.  Oncogene . 1999;  18 305-314
    CrossrefPubMedGoogle Scholar
  • 48 Yoon J-H, Higuchi H, Werneburg N W, Kaufmann S H, Gores G J. Bile acids induce cycloxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.  Gastroenterology . 2002;  122 905-993
    PubMedGoogle Scholar
  • 49 Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line.  J Gastroenterol Hepatol . 1994;  9 462-467
    PubMedGoogle Scholar
  • 50 Sugawara H, Yasoshima M, Katayanagi K. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma.  Histopathology . 1998;  33 145-153
    CrossrefPubMedGoogle Scholar
  • 51 Park J, Tadlock L, Gores G J, Patel T. Inhibition of interleukin-6 mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.  Hepatology . 1999;  30 1128-1133
    Google Scholar
  • 52 Yokomuro S, Tsuji H, Lunz III G J. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells.  Hepatology . 2000;  32 26-35
    CrossrefPubMedGoogle Scholar
  • 53 Qiu Y, Ravi L, Kung H-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.  Nature . 1998;  393 83-85
    CrossrefPubMedGoogle Scholar
  • 54 Jee S-H, Shen S-C, Chiu H-C, Tsai W-L, Kuo M-L. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency.  Oncogene . 2001;  20 198-208
    CrossrefPubMedGoogle Scholar
  • 55 Hinson R M, Williams J A, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2.  Proc Natl Acad Sci USA . 1996;  93 4885-4890
    CrossrefPubMedGoogle Scholar
  • 56 Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia.  Ann Clin Lab Sci . 2000;  30 3-21
    PubMedGoogle Scholar
  • 57 Liu X-H, Kirschenbaum A, Lu M. Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.  Biochem Biophys Res Commu . 2002;  290 249-255
    PubMedGoogle Scholar
  • 58 Zhang L, Chang C, Bacus S S, Hung M-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.  Cancer Res . 1995;  55 3890-3896
    PubMedGoogle Scholar
  • 59 Zhang L, Lau Y-K, Xia W, Hortobagyi G N, Hung M-C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.  Clin Cancer Res . 1999;  5 343-353
    PubMedGoogle Scholar
  • 60 Yu D, Hung M-C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.  Oncogene . 2000;  19 6115-6121
    CrossrefPubMedGoogle Scholar
  • 61 Arteaga C L, Chinratanalab W, Carter M B. Inhibitors of HER2/neu (erbB-2) signal transduction.  Semin Oncol . 2001;  28(Suppl 18) 30-35
    PubMedGoogle Scholar
  • 62 Slamon D J, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med . 2001;  344 783-792
    CrossrefPubMedGoogle Scholar
  • 63 Steinbach G, Lynch P M, Phillips R KS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med . 2000;  342 1946-1952
    CrossrefPubMedGoogle Scholar
  • 64 Cruz-Correa M, Hylind L M, Romans K E, Booker S V, Giardiello F M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.  Gastroenterology . 2002;  122 641-645
    CrossrefPubMedGoogle Scholar
  • 65 Mann M, Sheng H, Shao J. Targeting Cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.  Gastroenterology . 2001;  120 1713-1719
    PubMedGoogle Scholar